179 related articles for article (PubMed ID: 15726351)
1. Is whole-body FDG-PET valuable for health screening? Against.
Weckesser M; Schober O
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):342-3. PubMed ID: 15726351
[No Abstract] [Full Text] [Related]
2. Is whole-body FDG-PET valuable for health screening? For.
Ide M; Suzuki Y
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):339-41. PubMed ID: 15726352
[No Abstract] [Full Text] [Related]
3. A plea for the elective inclusion of the brain in routine whole-body FDG PET.
Belhocine T; Weiner SM; Brink I; De Deyn PP; Roland J; Van der Borght T; Flamen P
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):251-6. PubMed ID: 15692807
[No Abstract] [Full Text] [Related]
4. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Larson SM; Schwartz LH
J Nucl Med; 2006 Jun; 47(6):901-3. PubMed ID: 16741296
[No Abstract] [Full Text] [Related]
5. Source of impaired image quality in 3D whole-body FDG PET scanning.
Paans AM; Boerdijk SM; Willemsen AT; Pruim J
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1207; author reply 1208. PubMed ID: 15197498
[No Abstract] [Full Text] [Related]
6. 18F-FDG imaging: pitfalls and artifacts.
Abouzied MM; Crawford ES; Nabi HA
J Nucl Med Technol; 2005 Sep; 33(3):145-55; quiz 162-3. PubMed ID: 16145222
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG PET in the management of lymphoma: practical guidelines.
Kirby AM; George Mikhaeel N
Nucl Med Commun; 2007 May; 28(5):355-7. PubMed ID: 17414884
[TBL] [Abstract][Full Text] [Related]
8. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.
Kojima S; Zhou B; Teramukai S; Hara A; Kosaka N; Matsuo Y; Suzuki H; Torigoe S; Suzuki T; Uno K; Fukushima M
Eur J Cancer; 2007 Aug; 43(12):1842-8. PubMed ID: 17614273
[TBL] [Abstract][Full Text] [Related]
9. PET evaluation of lung cancer.
Bunyaviroch T; Coleman RE
J Nucl Med; 2006 Mar; 47(3):451-69. PubMed ID: 16513615
[No Abstract] [Full Text] [Related]
10. [Positron emission tomography/computed tomography with 18F-FDG. PET Working Group. Procedures Committee of the Spanish Society of Nuclear Medicine].
García Garzón JR; Rodríguez A; Cabrera A
Rev Esp Med Nucl; 2009; 28(2):85-9. PubMed ID: 19406058
[No Abstract] [Full Text] [Related]
11. [18F-FDG whole-body positron-emission tomography (PET) in patients with unknown primary tumors].
Matheja P; Schober O
Strahlenther Onkol; 2000 Mar; 176(3):151-2. PubMed ID: 10742838
[No Abstract] [Full Text] [Related]
12. PET: too much of a good thing? Does the plethora of choices impact on patient management?
Divgi C; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):398. PubMed ID: 15761778
[No Abstract] [Full Text] [Related]
13. Detecting residual fluorine 18 from a medical PET-CT procedure during population whole body counter screening in Fukushima.
Nishikawa Y; Tsubokura M; Kato S; Ishii T; Saito Y
Disaster Med Public Health Prep; 2014 Dec; 8(6):469-70. PubMed ID: 25859688
[No Abstract] [Full Text] [Related]
14. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
15. Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?
Basu S; Nair N
Nucl Med Commun; 2006 May; 27(5):413-6. PubMed ID: 16609351
[No Abstract] [Full Text] [Related]
16. Utility of 18F-FDG PET in evaluating cancers of lung.
Acker MR; Burrell SC
J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
[TBL] [Abstract][Full Text] [Related]
17. Defining optimal tracer activities in pediatric oncologic whole-body
Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF; Schäfer JF
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2283-2289. PubMed ID: 27565153
[TBL] [Abstract][Full Text] [Related]
18. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
Weber WA
J Nucl Med; 2007 Oct; 48(10):1580-2. PubMed ID: 17909256
[No Abstract] [Full Text] [Related]
20. Early clinical experience and impact of [18F]fluorodeoxyglucose positron emission tomography.
Akpinar AT
Nucl Med Commun; 2006 Apr; 27(4):405. PubMed ID: 16531929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
